UOC
RIGL icon

UBS O'Connor’s Rigel Pharmaceuticals RIGL Stock Holding History

UBS O'Connor’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-104,890
Closed -$1.96M – 419
2025
Q2 		$1.96M Sell
104,890
-5,494
-5% -$104K 0.05% 161
2025
Q1 		$1.99M Buy
110,384
+26,073
+31% +$529K 0.05% 124
2024
Q4 		$1.42M Sell
84,311
-32,604
-28% -$625K 0.04% 200
2024
Q3 		$1.89M Buy
116,915
+24,467
+26% +$288K 0.05% 184
2024
Q2 		$760K Buy
92,448
+25,173
+37% +$263K 0.02% 330
2024
Q1 		$996K Sell
67,275
-22,659
-25% -$305K 0.03% 276
2023
Q4 		$1.3M Sell
89,934
-25,243
-22% -$258K 0.04% 239
2023
Q3 		$1.24M Buy
115,177
+12,500
+12% +$150K 0.02% 305
2023
Q2 		$1.32M Buy
102,677
+26,926
+36% +$364K 0.03% 354
2023
Q1 		$1,000K Buy
+75,751
New +$1.2M 0.02% 404
2022
Q4 		– Sell
-28,614
Closed -$338K – 259
2022
Q3 		$338K Sell
28,614
-14,506
-34% -$196K ﹤0.01% 828
2022
Q2 		$487K Buy
+43,120
New +$866K 0.01% 819
2018
Q3 		– Sell
-45,000
Closed -$1.27M – 324
2018
Q2 		$1.27M Buy
+45,000
New +$1.6M 0.03% 192

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CLGM
Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS O'Connor's RIGL Position: Q3 2025 in Review

UBS O'Connor sold out of Rigel Pharmaceuticals (RIGL) in Q3 2025, closing a stake of 104,890 shares — an estimated $1.96M sold.

UBS O'Connor first reported a position in RIGL in Q2 2018 and held it in 13 quarters. The position peaked at $1.99M in Q1 2025. 169 funds tracked by Wall St. Rank hold RIGL as of Q3 2025.

  • UBS O'Connor reported no remaining Rigel Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 104,890 Rigel Pharmaceuticals shares in Q3 2025, an estimated $1.96M.
  • UBS O'Connor first reported a position in Rigel Pharmaceuticals in Q2 2018 and held it in 13 quarters.
  • UBS O'Connor's Rigel Pharmaceuticals position peaked at $1.99M in Q1 2025.
  • 169 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.